Status:

UNKNOWN

Clinical Proof-of-concept Study on Rapid Immune Modulating Effects

Lead Sponsor:

Natural Immune Systems Inc

Conditions:

Immune Surveillance

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

Clinical-proof-of concept study, comparing the acute immune impacts of of 2 doses of a novel blend of supplements to a placebo. This study involves twenty-four participants, composed of healthy adults...

Detailed Description

Clinical-proof-of-concept study comparing the acute immune effects of 2 doses of a nutraceutical blend, and a placebo. The nutraceutical blend is based on a transfer factor isolated from cow colostrum...

Eligibility Criteria

Inclusion

  • Healthy adults
  • Veins easy to see in one or both arms
  • Willing to comply with study procedures, including
  • Maintaining a consistent diet and lifestyle routine throughout the study;
  • Consistent habit of bland breakfast on days of clinic visits
  • Abstaining from exercising on and nutritional supplements on the morning of a study visit;
  • Abstaining from use of coffee, tea, and soft drinks for at least one hour prior to a clinic visit;
  • Abstaining from music, candy, gum, computer/cell phone use, during clinic visits

Exclusion

  • Previous major gastrointestinal surgery
  • Taking anti-inflammatory medications on a daily basis
  • Currently experiencing intense stressful events/life changes
  • Currently in intensive athletic training (such as marathon runner)
  • Currently taking antipsychotic medications such as clozapine, Risperdal, Abilify, Zyprexa or Seroquel
  • An unusual sleep routine
  • Unwilling to maintain a constant intake of supplements over the duration of the study
  • Anxiety about having blood drawn
  • People of childbearing potential: Pregnant, nursing, or trying to become pregnant
  • Known food sensitivities related to ingredients in active test product placebo Prescription medication evaluated on a cas-by-case basis

Key Trial Info

Start Date :

May 7 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2023

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT05364710

Start Date

May 7 2022

End Date

June 1 2023

Last Update

May 13 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

NIS Labs

Klamath Falls, Oregon, United States, 97601

Clinical Proof-of-concept Study on Rapid Immune Modulating Effects | DecenTrialz